

# Christopher R Chapple

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3813401/christopher-r-chapple-publications-by-citations.pdf>

**Version:** 2023-03-30

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

594  
papers

31,814  
citations

81  
h-index

166  
g-index

780  
ext. papers

36,072  
ext. citations

4.3  
avg, IF

7.1  
L-index

#	Paper	IF	Citations
593	The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. <i>Neurourology and Urodynamics</i> , <b>2002</b> , 21, 167-78 <sup>2,3</sup>		5149
592	The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. <i>Urology</i> , <b>2003</b> , 61, 37-49	1.5	2088
591	EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. <i>European Urology</i> , <b>2013</b> , 64, 118-40	9.9	799
590	The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. <i>American Journal of Obstetrics and Gynecology</i> , <b>2002</b> , 187, 116-26	1.9	772
589	Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. <i>Neurourology and Urodynamics</i> , <b>2010</b> , 29, 213-40	2.3	750
588	The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. <i>European Urology</i> , <b>2008</b> , 54, 543-62	9.9	558
587	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. <i>European Urology</i> , <b>2015</b> , 67, 1099-1109	9.9	525
586	The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. <i>BJU International</i> , <b>2009</b> , 104, 352-60	5.4	462
585	Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. <i>Urology</i> , <b>2001</b> , 57, 414-21	1.5	394
584	Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. <i>British Journal of Pharmacology</i> , <b>2006</b> , 148, 565-78	8.3	390
583	A randomized trial of urodynamic testing before stress-incontinence surgery. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1987-97	57.2	332
582	Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. <i>BJU International</i> , <b>2004</b> , 93, 303-10	5.4	306
581	Efficacy and tolerability of mirabegron, a $\beta$ -adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. <i>European Urology</i> , <b>2013</b> , 63, 283-93 <sup>9</sup>	9.9	296
580	Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. <i>Journal of Urology</i> , <b>2010</b> , 184, 2416-22	1.5	290
579	A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. <i>European Urology</i> , <b>2006</b> , 49, 651-8	9.9	269
578	A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. <i>European Urology</i> , <b>2005</b> , 48, 464-70	9.9	246
577	Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence. <i>European Urology</i> , <b>2010</b> , 58, 218-38	9.9	261

576	Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a $\beta$ -adrenoceptor agonist, in overactive bladder. <i>European Urology</i> , <b>2013</b> , 63, 296-305	9.9	248
575	Refractory idiopathic urge urinary incontinence and botulinum A injection. <i>Journal of Urology</i> , <b>2008</b> , 180, 217-22	1.5	248
574	EAU guidelines on urinary incontinence. <i>European Urology</i> , <b>2011</b> , 59, 387-400	9.9	246
573	OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. <i>European Urology</i> , <b>2013</b> , 64, 249-56	9.9	244
572	Muscarinic receptor antagonists in the treatment of overactive bladder. <i>Urology</i> , <b>2000</b> , 55, 33-46; discussion 50	1.5	233
571	Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. <i>European Urology</i> , <b>2014</b> , 65, 389-98	9.9	227
570	The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire. <i>British Journal of Urology</i> , <b>1996</b> , 77, 554-62		218
569	Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. <i>British Journal of Pharmacology</i> , <b>2000</b> , 129, 416-9	8.3	210
568	Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. <i>Journal of Urology</i> , <b>2006</b> , 175, 999-1004; discussion 1004	1.5	212
567	Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. <i>European Urology</i> , <b>2007</b> , 52, 1204-12	9.9	193
566	Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. <i>European Urology</i> , <b>2012</b> , 61, 917-25	9.9	197
565	Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. <i>European Urology</i> , <b>2011</b> , 59, 342-52	9.9	194
564	A new treatment for urethral strictures. <i>Lancet, The</i> , <b>1988</b> , 1, 1424-7	36.2	188
563	The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. <i>European Urology</i> , <b>2005</b> , 48, 5-26	9.9	180
562	The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 433-477	2.3	178
561	The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. <i>BJU International</i> , <b>2005</b> , 95, 335-40	5.4	180
560	Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33, 17-30	2.3	171
559	A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. <i>European Urology</i> , <b>2012</b> , 62, 877-90	9.9	179

558	Evaluation and treatment of lower urinary tract symptoms in older men. <i>Journal of Urology</i> , <b>2009</b> , 181, 1779-87	1.5	167
557	Tissue-engineered buccal mucosa urethroplasty-clinical outcomes. <i>European Urology</i> , <b>2008</b> , 53, 1263-9	9.9	165
556	Buccal mucosal urethroplasty: is it the new gold standard?. <i>BJU International</i> , <b>2004</b> , 93, 1191-3	5.4	156
555	Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. <i>BJU International</i> , <b>2009</b> , 103 Suppl 3, 24-32	5.4	152
554	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. <i>Current Opinion in Urology</i> , <b>2009</b> , 19, 380-94	2.7	138
553	The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. <i>BJU International</i> , <b>2009</b> , 103 Suppl 3, 12-23	5.4	141
552	Consensus statement on urethral trauma. <i>BJU International</i> , <b>2004</b> , 93, 1195-202	5.4	140
551	An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. <i>International Urogynecology Journal</i> , <b>2017</b> , 28, 191-213	2	140
550	Bladder Pain Syndrome Committee of the International Consultation on Incontinence. <i>Neurourology and Urodynamics</i> , <b>2010</b> , 29, 191-8	2.3	140
549	Lower urinary tract symptoms revisited: a broader clinical perspective. <i>European Urology</i> , <b>2008</b> , 54, 563-9	9.9	140
548	Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. <i>BJU International</i> , <b>2004</b> , 93, 71-7	5.4	132
547	Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. <i>European Urology</i> , <b>2009</b> , 56, 534-41	9.9	130
546	A systematic review of graft augmentation urethroplasty techniques for the treatment of anterior urethral strictures. <i>European Urology</i> , <b>2011</b> , 59, 797-814	9.9	135
545	A review of adherence to drug therapy in patients with overactive bladder. <i>BJU International</i> , <b>2008</b> , 102, 774-9	5.4	129
544	The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. <i>Autonomic and Autacoid Pharmacology</i> , <b>2001</b> , 21, 243-8		126
543	Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. <i>European Urology</i> , <b>2008</b> , 54, 419-26	9.9	120
542	Defining a patient-reported outcome measure for urethral stricture surgery. <i>European Urology</i> , <b>2011</b> , 60, 60-8	9.9	132
541	Bladder afferent sensitivity in wild-type and TRPV1 knockout mice. <i>Journal of Physiology</i> , <b>2007</b> , 583, 663-74	3.74	123

540	Pelvic organ prolapse and overactive bladder. <i>Neurourology and Urodynamics</i> , <b>2010</b> , 29, 30-9	2.3	122
539	An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. <i>European Urology</i> , <b>2014</b> , 65, 981-90	9.9	117
538	Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. <i>BJU International</i> , <b>2005</b> , 95, 81-5	5.4	115
537	A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. <i>BJU International</i> , <b>2005</b> , 95, 993-1001	5.4	113
536	Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. <i>Neurourology and Urodynamics</i> , <b>2011</b> , 30, 306-11	2.3	116
535	Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. <i>European Urology</i> , <b>2005</b> , 47, 376-84	9.9	107
534	Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. <i>European Urology</i> , <b>2012</b> , 61, 520-9	9.9	114
533	Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?. <i>BJU International</i> , <b>2007</b> , 99, 749-52	5.4	112
532	Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. <i>European Urology</i> , <b>2017</b> , 72, 424-431	9.9	111
531	SIU/ICUD Consultation on Urethral Strictures: The management of anterior urethral stricture disease using substitution urethroplasty. <i>Urology</i> , <b>2014</b> , 83, S31-47	1.5	114
530	A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. <i>British Journal of Urology</i> , <b>1994</b> , 74, 50-6		108
529	Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. <i>European Urology</i> , <b>2017</b> , 72, 389-399	9.9	114
528	Muscarinic receptor subtypes and management of the overactive bladder. <i>Urology</i> , <b>2002</b> , 60, 82-8; discussion 88-9	1.5	104
527	Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). <i>European Urology</i> , <b>2016</b> , 70, 136-145	9.9	112
526	An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. <i>Neurourology and Urodynamics</i> , <b>2017</b> , 36, 221-244	2.3	99
525	The underactive bladder: a new clinical concept?. <i>European Urology</i> , <b>2015</b> , 68, 351-3	9.9	99
524	A phase II dose-ranging study of mirabegron in patients with overactive bladder. <i>International Urogynecology Journal</i> , <b>2013</b> , 24, 1447-58	2	98
523	Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. <i>Clinical Therapeutics</i> , <b>2001</b> , 23, 1245-59	3.4	94

522	Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. <i>Obstetrics and Gynecology</i> , <b>2008</b> , 112, 1311-1318	2	89
521	The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. <i>British Journal of Pharmacology</i> , <b>1997</b> , 120, 231-8	8.3	90
520	A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. <i>European Urology</i> , <b>2009</b> , 56, 810-9	9.9	89
519	Which muscarinic receptor is important in the bladder?. <i>World Journal of Urology</i> , <b>2001</b> , 19, 299-306	3.9	88
518	Urinary incontinence in frail elderly persons: Report from the 5th International Consultation on Incontinence. <i>Neurourology and Urodynamics</i> , <b>2015</b> , 34, 398-406	2.3	87
517	Tissue-engineered buccal mucosa for substitution urethroplasty. <i>BJU International</i> , <b>2004</b> , 93, 807-11	5.4	86
516	A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. <i>European Urology</i> , <b>2019</b> , 75, 988-1000	9.9	88
515	Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). <i>BJU International</i> , <b>2017</b> , 120, 562-575	5.4	87
514	Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. <i>BJU International</i> , <b>2004</b> , 94, 738-44	5.4	81
513	Efficacy of tiroprium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. <i>BJU International</i> , <b>2000</b> , 85, 659-64	5.4	81
512	Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. <i>Journal of the American Geriatrics Society</i> , <b>2013</b> , 61, 185-93	5.4	78
511	Reanalysis of a randomized trial of 3 techniques of anterior colporrhaphy using clinically relevant definitions of success. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 205, 69.e1-8	1.9	81
510	Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. <i>Urology</i> , <b>2006</b> , 68, 3-8	1.5	75
509	Surgical techniques in substitution urethroplasty using buccal mucosa for the treatment of anterior urethral strictures. <i>European Urology</i> , <b>2008</b> , 53, 1162-71	9.9	81
508	Solifenacin significantly improves all symptoms of overactive bladder syndrome. <i>International Journal of Clinical Practice</i> , <b>2006</b> , 60, 959-66	2.8	73
507	The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. <i>Urology</i> , <b>2006</b> , 68, 38-48	1.5	75
506	Darifenacin treatment of patients $\geq 65$ years with overactive bladder: results of a randomized, controlled, 12-week trial. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2347-58	2.5	75
505	Comparison of fesoterodine and tolterodine in patients with overactive bladder. <i>BJU International</i> , <b>2008</b> , 102, 1128-32	5.4	71

504	Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. <i>European Urology</i> , <b>2006</b> , 50, 684-709; discussion 709-10	9.9	70
503	In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. <i>British Journal of Pharmacology</i> , <b>1999</b> , 127, 252-8	8.3	71
502	Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). <i>Age and Ageing</i> , <b>2015</b> , 44, 745-55	2.8	71
501	A proof-of-concept study: mirabegron, a new therapy for overactive bladder. <i>Neurourology and Urodynamics</i> , <b>2013</b> , 32, 1116-22	2.3	70
500	Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. <i>International Journal of Clinical Practice</i> , <b>2011</b> , 65, 487-507	2.8	68
499	It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. <i>British Journal of Health Psychology</i> , <b>2008</b> , 13, 343-59	8	66
498	European psychometric validation of the CONTILIFE: a Quality of Life questionnaire for urinary incontinence. <i>European Urology</i> , <b>2003</b> , 43, 391-404	9.9	69
497	The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. <i>British Journal of Urology</i> , <b>1994</b> , 73, 117-23		68
496	Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. <i>European Urology</i> , <b>2013</b> , 64, 228-43	9.9	68
495	Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. <i>European Urology</i> , <b>2013</b> , 64, 1003-12	9.9	64
494	A systematic review of surgical techniques used in the treatment of female urethral stricture. <i>European Urology</i> , <b>2013</b> , 64, 965-73	9.9	66
493	Cardiovascular Safety of $\beta$ -adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. <i>European Urology</i> , <b>2016</b> , 69, 311-23	9.9	63
492	Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. <i>Journal of Urology</i> , <b>2016</b> , 196, 791-800	1.5	62
491	In vitro release of adenosine triphosphate from the urothelium of human bladders with detrusor overactivity, both neurogenic and idiopathic. <i>European Urology</i> , <b>2010</b> , 57, 1087-92	9.9	62
490	A prospective patient-centred evaluation of urethroplasty for anterior urethral stricture using a validated patient-reported outcome measure. <i>European Urology</i> , <b>2013</b> , 64, 777-82	9.9	63
489	Enhanced adenosine triphosphate release from the urothelium of patients with painful bladder syndrome: a possible pathophysiological explanation. <i>Journal of Urology</i> , <b>2007</b> , 178, 1533-6	1.5	60
488	Results of the tension-free vaginal tape technique in the elderly. <i>European Urology</i> , <b>2003</b> , 44, 128-31	9.9	58
487	The role of M(2)-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. <i>British Journal of Pharmacology</i> , <b>2000</b> , 131, 1482-8	8.3	58

486	Age-related changes in afferent pathways and urothelial function in the male mouse bladder. <i>Journal of Physiology</i> , <b>2014</b> , 592, 537-49	3.8	59
485	What are the causes and consequences of bladder overdistension? ICI-RS 2011. <i>Neurourology and Urodynamics</i> , <b>2012</b> , 31, 317-21	2.3	59
484	International Continence Society consensus on the diagnosis and treatment of nocturia. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 478-498	2.3	58
483	Comparison of candidate scaffolds for tissue engineering for stress urinary incontinence and pelvic organ prolapse repair. <i>BJU International</i> , <b>2013</b> , 112, 674-85	5.4	53
482	OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. <i>BJU International</i> , <b>2013</b> , 112, 1018-26	5.4	56
481	Overactive bladder syndrome in older people. <i>BJU International</i> , <b>2007</b> , 99, 502-9	5.4	54
480	Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. <i>European Urology</i> , <b>2007</b> , 52, 1195-203	9.9	51
479	Evaluation and treatment of lower urinary tract symptoms in older men. <i>Journal of Urology</i> , <b>2013</b> , 189, S93-S101	1.5	53
478	Developing biodegradable scaffolds for tissue engineering of the urethra. <i>BJU International</i> , <b>2011</b> , 107, 296-302	5.4	56
477	Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. <i>Urology</i> , <b>2008</b> , 72, 803-7	1.5	53
476	A practical approach to the management of nocturia. <i>International Journal of Clinical Practice</i> , <b>2017</b> , 71, e13027	2.8	54
475	Basic mechanisms of urgency: preclinical and clinical evidence. <i>European Urology</i> , <b>2009</b> , 56, 298-307	9.9	54
474	The role of the urothelium in mediating bladder responses to isoprenaline. <i>BJU International</i> , <b>2007</b> , 99, 669-73	5.4	53
473	Safety and tolerability of the $\beta$ -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. <i>International Journal of Clinical Practice</i> , <b>2014</b> , 68, 972-85	2.8	50
472	Developing a tissue engineered repair material for treatment of stress urinary incontinence and pelvic organ prolapse-which cell source?. <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33, 531-7	2.3	52
471	Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). <i>European Urology</i> , <b>2013</b> , 64, 398-407	9.9	51
470	OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. <i>Neurourology and Urodynamics</i> , <b>2013</b> , 32, 1109-15	2.3	53
469	An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence. <i>European Urology</i> , <b>2005</b> , 48, 488-94	9.9	50



468	The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. <i>European Urology</i> , <b>2011</b> , 60, 94-105	9.9	49
467	Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study. <i>European Urology</i> , <b>2006</b> , 49, 92-102	9.9	47
466	Overactive bladder: Is there a link to the metabolic syndrome in men?. <i>Neurourology and Urodynamics</i> , <b>2010</b> , 29, 1360-4	2.3	49
465	Fowler's syndrome--a cause of unexplained urinary retention in young women?. <i>Nature Reviews Urology</i> , <b>2014</b> , 11, 87-98	5.3	47
464	Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 199-217	2.8	48
463	Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. <i>International Journal of Clinical Practice</i> , <b>2013</b> , 67, 606-18	2.8	49
462	Cholinergic innervation and muscarinic receptors in the human prostate. <i>European Urology</i> , <b>2008</b> , 54, 326-34	9.9	48
461	Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. <i>European Urology</i> , <b>2015</b> , 67, 262-70	9.9	47
460	Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. <i>European Urology</i> , <b>2007</b> , 52, 531-8	9.9	45
459	Recent advances in basic science for overactive bladder. <i>Current Opinion in Urology</i> , <b>2005</b> , 15, 222-6	2.7	45
458	Characteristics of patients presenting with LUTS/BPH in six European countries. <i>European Urology</i> , <b>2006</b> , 50, 555-61; discussion 562	9.9	47
457	Does central sensitization help explain idiopathic overactive bladder?. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 481-91	5.3	44
456	Management of symptomatic urethral diverticula in women: a single-centre experience. <i>European Urology</i> , <b>2014</b> , 66, 164-72	9.9	44
455	Assessing patients' descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 1260-78	2.8	44
454	Management of lower urinary tract symptoms in men: summary of NICE guidance. <i>BMJ, The</i> , <b>2010</b> , 340, c2354	5.7	50
453	Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. <i>International Journal of Urology</i> , <b>2006</b> , 13, 692-8	2.2	44
452	Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 197-204	3.7	44
451	Recent developments in the management of detrusor overactivity. <i>Current Opinion in Urology</i> , <b>2003</b> , 13, 285-91	2.7	42

450	Pelvic floor muscle activation and strength components influencing female urinary continence and stress incontinence: a systematic review. <i>Neurourology and Urodynamics</i> , <b>2015</b> , 34, 498-506	2.3	41
449	Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB). <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 2928-2931	2.3	43
448	OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. <i>International Journal of Clinical Practice</i> , <b>2014</b> , 68, 1246-56	2.8	42
447	Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. <i>European Urology</i> , <b>2013</b> , 64, 610-21	9.9	42
446	Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review. <i>Neurourology and Urodynamics</i> , <b>2012</b> , 31, 13-21	2.3	41
445	Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD09471L/0004). <i>European Urology</i> , <b>2006</b> , 49, 879-889	8.9	39
444	The role of beta(3)-adrenoceptors in mediating relaxation of porcine detrusor muscle. <i>British Journal of Pharmacology</i> , <b>2002</b> , 135, 129-34	8.3	42
443	Stress incontinence injection therapy: what is best for our patients?. <i>European Urology</i> , <b>2005</b> , 48, 552-65	9.9	41
442	Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. <i>BJU International</i> , <b>2017</b> , 120, 611-622	5.4	40
441	The $\beta$ -adrenoceptor mediates the inhibitory effects of $\beta$ -adrenoceptor agonists via the urothelium in pig bladder dome. <i>Neurourology and Urodynamics</i> , <b>2010</b> , 29, 1320-5	2.3	39
440	Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). <i>European Urology</i> , <b>2007</b> , 52, 230-7	9.9	39
439	Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies. <i>European Urology</i> , <b>2018</b> , 74, 633-643	9.9	39
438	Tissue engineering in urethral reconstruction--an update. <i>Asian Journal of Andrology</i> , <b>2013</b> , 15, 89-92	2.7	38
437	Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. <i>World Journal of Urology</i> , <b>2012</b> , 30, 385-92	3.9	40
436	Qualitative Exploration of the Patient Experience of Underactive Bladder. <i>European Urology</i> , <b>2017</b> , 72, 402-407	9.9	41
435	Female urethral diverticula. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 248-54	2.7	38
434	Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. <i>British Journal of Pharmacology</i> , <b>1995</b> , 116, 1605-10	8.3	38
433	Tissue engineered buccal mucosa for urethroplasty: progress and future directions. <i>Advanced Drug Delivery Reviews</i> , <b>2015</b> , 82-83, 69-76	17.9	37

432	Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33, 106-14	2.3	36
431	Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. <i>Urology</i> , <b>2010</b> , 75, 1149-55	1.5	37
430	The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity. <i>European Urology</i> , <b>2010</b> , 58, 22-8; discussion 31-2	9.9	35
429	Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries. <i>Life Sciences</i> , <b>2008</b> , 83, 569-73	6.6	37
428	OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. <i>Neurology</i> , <b>2013</b> , 81, 841-8	5.7	36
427	Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. <i>International Journal of Urology</i> , <b>2018</b> , 25, 196-205	2.2	36
426	A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. <i>BJU International</i> , <b>2007</b> , 99, 355-9	5.4	36
425	Nitric oxide is involved in the non-adrenergic, non-cholinergic inhibitory neurotransmission of the pig intravesical ureter. <i>Neuroscience Letters</i> , <b>1995</b> , 186, 33-6	3.2	36
424	Efficacy of the $\beta$ -adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. <i>European Urology</i> , <b>2015</b> , 67, 11-14	9.9	32
423	Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "overactive bladder". <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33 Suppl 3, S6-13	2.3	35
422	Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. <i>European Urology</i> , <b>1999</b> , 35, 119-28	9.9	35
421	The placebo effect in overactive bladder syndrome. <i>Nature Reviews Urology</i> , <b>2011</b> , 8, 495-503	5.3	35
420	The afferent system and its role in lower urinary tract dysfunction. <i>Current Opinion in Urology</i> , <b>2011</b> , 21, 268-74	2.7	35
419	Management of anterior urethral stricture: an evidence-based approach. <i>Current Opinion in Urology</i> , <b>2010</b> , 20, 453-8	2.7	34
418	Tamsulosin: an overview. <i>World Journal of Urology</i> , <b>2002</b> , 19, 397-404	3.9	34
417	Validation of the urinary sensation scale (USS). <i>Neurourology and Urodynamics</i> , <b>2011</b> , 30, 360-5	2.3	32
416	Are slings now the gold standard treatment for the management of female urinary stress incontinence and if so which technique?. <i>Current Opinion in Urology</i> , <b>2003</b> , 13, 301-7	2.7	34
415	Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. <i>International Journal of Urology</i> , <b>2014</b> , 21, 960-7	2.2	34

414	Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. <i>World Journal of Urology</i> , <b>2014</b> , 32, 1119-25	3.9	33
413	Determining the variables associated to clean intermittent self-catheterization adherence rate: one-year follow-up study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2011</b> , 37, 766-72	2	31
412	Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. <i>BJU International</i> , <b>2009</b> , 104, 960-7	5.4	34
411	Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. <i>Current Opinion in Urology</i> , <b>2010</b> , 20, 43-8	2.7	33
410	Spontaneous contractions of the pig urinary bladder: the effect of ATP-sensitive potassium channels and the role of the mucosa. <i>BJU International</i> , <b>2008</b> , 102, 1168-74	5.4	30
409	Vesico-vaginal fistula. <i>BJU International</i> , <b>2005</b> , 95, 193-214	5.4	32
408	Pencil and paper test: a new tool to predict the ability of neurological patients to practice clean intermittent self-catheterization. <i>Journal of Urology</i> , <b>2011</b> , 185, 578-82	1.5	29
407	Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 1103-1110	1	28
406	Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. <i>Neurourology and Urodynamics</i> , <b>2003</b> , 22, 338-42	2.3	30
405	Urodynamics For Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for diagnosis and management of bladder outlet obstruction in men: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2015</b> , 16, 567	2.7	34
404	The cost of preoperative urodynamics: A secondary analysis of the VALUE trial. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 81-4	2.3	28
403	Do patients with symptoms and signs of lower urinary tract dysfunction need a urodynamic diagnosis? ICI-RS 2013. <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33, 581-6	2.3	29
402	Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK. <i>International Journal of Clinical Practice</i> , <b>2008</b> , 62, 688-94	2.8	29
401	Rising awareness of the complications of synthetic slings. <i>Current Opinion in Urology</i> , <b>2004</b> , 14, 317-21	2.7	29
400	Demonstration of improved tissue integration and angiogenesis with an elastic, estradiol releasing polyurethane material designed for use in pelvic floor repair. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 716-725	2.3	27
399	Evaluating Alternative Materials for the Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse: A Comparison of the In Vivo Response to Meshes Implanted in Rabbits. <i>Journal of Urology</i> , <b>2016</b> , 196, 261-9	1.5	28
398	Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. <i>Therapeutic Advances in Urology</i> , <b>2017</b> , 9, 137-154	3.1	27
397	Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome. <i>Neurourology and Urodynamics</i> , <b>2011</b> , 30, 1467-72	2.3	28

396	Abnormal pelvic response to cough in women with stress urinary incontinence. <i>Neurourology and Urodynamics</i> , <b>2008</b> , 27, 291-6	2.3	28
395	Transurethral implantation of silicone polymer for stress incontinence: evaluation of a porcine model and mechanism of action in vivo. <i>BJU International</i> , <b>2000</b> , 85, 646-50	5.4	28
394	Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , <b>2004</b> , 13, 1493-500	5.7	28
393	Urethral injury. <i>BJU International</i> , <b>2000</b> , 86, 318-26	5.4	26
392	Cardiovascular and ocular safety of $\alpha$ -adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 1187-97	4	28
391	Long-term follow-up after tissue-engineered buccal mucosa urethroplasty. <i>European Urology</i> , <b>2014</b> , 66, 790-1	9.9	26
390	Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. <i>Journal of Urology</i> , <b>2014</b> , 191, 253-60	1.5	27
389	Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice. <i>BJU International</i> , <b>2012</b> , 110, 710-8	5.4	27
388	Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 131-151	3.7	27
387	Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil. <i>BJU International</i> , <b>2010</b> , 106, 78-83	5.4	27
386	5-hydroxytryptamine induced relaxation in the pig urinary bladder neck. <i>British Journal of Pharmacology</i> , <b>2009</b> , 157, 271-80	8.3	27
385	Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study. <i>European Urology Supplements</i> , <b>2005</b> , 4, 33-44	0.1	26
384	(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 379-86	4.5	27
383	Contemporary management of urethral trauma and the post-traumatic stricture. <i>Current Opinion in Urology</i> , <b>1999</b> , 9, 253-60	2.7	24
382	Production of ascorbic acid releasing biomaterials for pelvic floor repair. <i>Acta Biomaterialia</i> , <b>2016</b> , 29, 188-197	10.5	25
381	Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. <i>Journal of Urology</i> , <b>2015</b> , 193, 1581-9	1.5	25
380	Mechanisms of bladder smooth-muscle hypertrophy and decompensation: lessons from normal development and the response to outlet obstruction. <i>World Journal of Urology</i> , <b>1998</b> , 16, 350-8	3.9	25
379	Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an $\beta$ -blocker: effect of baseline prostate-specific antigen concentration. <i>BJU International</i> , <b>2010</b> , 106, 1332-8	5.4	23

378	Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2085-96	3.9	24
377	Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). <i>BJU International</i> , <b>2013</b> , 111, 804-10	5.4	22
376	Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. <i>BJU International</i> , <b>2009</b> , 103 Suppl 3, 48-57	5.4	23
375	Intermittent catheterization difficulty questionnaire (ICDQ): A new tool for the evaluation of patient difficulties with clean intermittent self-catheterization. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 85-9	2.3	21
374	Onset of action of the $\beta$ -adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. <i>World Journal of Urology</i> , <b>2014</b> , 32, 1565-72	3.9	22
373	Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. <i>BJU International</i> , <b>2014</b> , 114, 418-26	5.4	21
372	Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. <i>World Journal of Urology</i> , <b>2013</b> , 31, 997-1008	3.9	22
371	Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. <i>BJU International</i> , <b>2008</b> , 102, 1651-7	5.4	22
370	Complications related to use of mesh implants in surgical treatment of stress urinary incontinence and pelvic organ prolapse: infection or inflammation?. <i>World Journal of Urology</i> , <b>2020</b> , 38, 73-80	3.9	23
369	Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. <i>Journal of Urology</i> , <b>2007</b> , 177, 1047-51; discussion 1051	1.5	22
368	A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. <i>Age and Ageing</i> , <b>2017</b> , 46, 620-626	2.8	22
367	Overactive bladder: The importance of new guidance. <i>International Journal of Clinical Practice</i> , <b>2006</b> , 60, 1263-71	2.8	21
366	The Impact of Nocturia in Patients with LUTS/BPH: Need for New Recommendations. <i>European Urology Supplements</i> , <b>2006</b> , 5, 12-18	0.1	21
365	Factors involved in the success of antimuscarinic treatment. <i>BJU International</i> , <b>1999</b> , 83 Suppl 2, 42-7	5.4	21
364	National study of utilization of male incontinence procedures. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 74-80	2.3	20
363	How can we develop a more clinically useful and robust algorithm for diagnosing and treating nocturia? ICI-RS 2017. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, S46-S59	2.3	21
362	Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review. <i>Urology</i> , <b>2015</b> , 86, 654-65	1.5	19
361	Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. <i>European Urology</i> , <b>2020</b> , 77, 119-128	9.9	23

360	The Neuro-Urological Connection. <i>European Urology Supplements</i> , <b>2005</b> , 4, 18-28	0.1	19
359	Nocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real-life practice database containing 8659 European and US-American patients. <i>International Journal of Clinical Practice</i> , <b>2016</b> , 70, 940-949	2.8	21
358	The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 48-54	2.3	19
357	Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. <i>BJU International</i> , <b>2014</b> , 113, 696-703	5.4	19
356	Antimuscarinics and $\beta$ -blockers or $\beta$ -blockers monotherapy on lower urinary tract symptoms--a meta-analysis. <i>Urology</i> , <b>2014</b> , 83, 556-62	1.5	20
355	Methods to reduce the contraction of tissue-engineered buccal mucosa for use in substitution urethroplasty. <i>European Urology</i> , <b>2011</b> , 60, 856-61	9.9	20
354	Management of the failure of a permanently implanted urethral stent--a therapeutic challenge. <i>European Urology</i> , <b>2008</b> , 54, 665-70	9.9	19
353	Urodynamics in the management of female stress incontinence--which test and when?. <i>Current Opinion in Urology</i> , <b>2008</b> , 18, 359-64	2.7	17
352	Benign prostatic hyperplasia: treatment in primary care. <i>BMJ, The</i> , <b>2006</b> , 333, 535-9	5.7	19
351	A rational approach to benign prostatic hyperplasia evaluation: recent advances. <i>Current Opinion in Urology</i> , <b>2004</b> , 14, 1-6	2.7	19
350	Involvement of a glibenclamide-sensitive mechanism in the nitrgic neurotransmission of the pig intravesical ureter. <i>British Journal of Pharmacology</i> , <b>1997</b> , 120, 609-16	8.3	19
349	Overcoming scarring in the urethra: Challenges for tissue engineering. <i>Asian Journal of Urology</i> , <b>2018</b> , 5, 69-77	2.5	19
348	Landmarks in vaginal mesh development: polypropylene mesh for treatment of SUI and POP. <i>Nature Reviews Urology</i> , <b>2019</b> , 16, 675-689	5.3	18
347	Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?. <i>BJU International</i> , <b>2016</b> , 118, 464-74	5.4	18
346	Assessment of Electrospun and Ultra-lightweight Polypropylene Meshes in the Sheep Model for Vaginal Surgery. <i>European Urology Focus</i> , <b>2020</b> , 6, 190-198	4.9	18
345	PACAP 38 is involved in the non-adrenergic non-cholinergic inhibitory neurotransmission in the pig urinary bladder neck. <i>Neurourology and Urodynamics</i> , <b>2006</b> , 25, 490-7	2.3	18
344	Pre-junctional alpha2-adrenoceptors modulation of the nitrgic transmission in the pig urinary bladder neck. <i>Neurourology and Urodynamics</i> , <b>2007</b> , 26, 578-583	2.3	18
343	Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. <i>Drugs in R and D</i> , <b>2002</b> , 3, 75-81	3.3	18

342	A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?. <i>European Urology</i> , <b>2016</b> , 70, 799-805	9.9	19
341	Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). <i>European Urology</i> , <b>2006</b> , 49, 501-8; discussion 508-9	9.9	16
340	Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunction-one, both or none?. <i>Nature Reviews Urology</i> , <b>2005</b> , 2, 555-64		17
339	Heterogeneity of neuronal and smooth muscle receptors involved in the VIP- and PACAP-induced relaxations of the pig intravesical ureter. <i>British Journal of Pharmacology</i> , <b>2004</b> , 141, 123-31	8.3	17
338	A critical review of diagnostic criteria for evaluating patients with symptomatic stress urinary incontinence. <i>BJU International</i> , <b>2005</b> , 95, 327-34	5.4	18
337	Is there any difference in pelvic floor muscles performance between continent and incontinent women?. <i>Neurourology and Urodynamics</i> , <b>2015</b> , 34, 544-8	2.3	16
336	Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials. <i>European Urology</i> , <b>2015</b> , 67, 114-122	9.9	18
335	Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1201-43	2.5	15
334	The Role of Nitric Oxide and Hydrogen Sulfide in Urinary Tract Function. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 119 Suppl 3, 34-41	3	18
333	Noradrenergic vasoconstriction of pig prostatic small arteries. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2008</b> , 376, 397-406	3.3	16
332	Definition of normality of pressure-flow parameters based on observations in asymptomatic men. <i>Neurourology and Urodynamics</i> , <b>2008</b> , 27, 388-94	2.3	16
331	Basic mechanisms of urgency: roles and benefits of pharmacotherapy. <i>World Journal of Urology</i> , <b>2009</b> , 27, 705-9	3.9	18
330	A multicenter, double-blind, randomized, parallel group study comparing polyvinyl chloride and polyvinyl chloride-free catheter materials. <i>Journal of Urology</i> , <b>2009</b> , 182, 2794-8	1.5	16
329	The underactive bladder: detection and diagnosis. <i>F1000Research</i> , <b>2016</b> , 5,	3.5	16
328	Patient-perceived outcomes in the treatment of stress urinary incontinence: focus on urethral injection therapy. <i>International Urogynecology Journal</i> , <b>2007</b> , 18, 199-205	2	15
327	Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients. <i>Drugs and Aging</i> , <b>2015</b> , 32, 103-25	4.5	14
326	Patient-reported outcomes with the $\beta$ adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 987-994	2.3	15
325	An Improved Methodology to Visualise Tumour Induced Changes in Vasculature Using the Chick Chorionic Allantoic Membrane Assay. <i>In Vivo</i> , <b>2018</b> , 32, 461-472	2.2	14



324	A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). <i>BJU International</i> , <b>2014</b> , 114, 427-33	5.4	16
323	Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences?. <i>International Journal of Clinical Practice</i> , <b>2014</b> , 68, 356-62	2.8	15
322	The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. <i>Research and Reports in Urology</i> , <b>2013</b> , 5, 99-111	1.2	14
321	Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. <i>European Urology</i> , <b>2020</b> , 78, 701-710	9.9	15
320	Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). <i>International Journal of Clinical Practice</i> , <b>2017</b> , 71, e12944	2.8	16
319	Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle. <i>European Urology</i> , <b>2006</b> , 49, 510-8	9.9	16
318	Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 2421-34	3.9	10
317	Nocturia: morbidity and management in adults. <i>International Journal of Clinical Practice</i> , <b>2005</b> , 59, 938-45.	5.8	15
316	Pharmacological characterization of A-131701, a novel $\alpha$ -adrenoceptor antagonist selective for $\alpha$ A- and $\alpha$ D-compared to $\alpha$ B-adrenoceptors. <i>Drug Development Research</i> , <b>1998</b> , 44, 140-162	4.9	13
315	Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials. <i>Journal of Urology</i> , <b>2018</b> , 200, 604-611	1.5	15
314	Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. <i>BJU International</i> , <b>2015</b> , 115, 802-14	5.4	15
313	Involuntary reflexive pelvic floor muscle training in addition to standard training versus standard training alone for women with stress urinary incontinence: study protocol for a randomized controlled trial. <i>Trials</i> , <b>2015</b> , 16, 524	2.7	14
312	Mechanisms involved in testosterone-induced relaxation to the pig urinary bladder neck. <i>Steroids</i> , <b>2012</b> , 77, 394-402	2.7	14
311	Medical management of lower urinary tract symptoms in men: current treatment and future approaches. <i>Nature Reviews Urology</i> , <b>2008</b> , 5, 211-9		14
310	Penile Paraffinoma. <i>European Urology Focus</i> , <b>2019</b> , 5, 894-898	4.9	15
309	Overview consensus statement. <i>Urology</i> , <b>2002</b> , 60, 1-6	1.5	14
308	The urgency of the problem and the problem of urgency in the overactive bladder. <i>BJU International</i> , <b>2005</b> , 95, 274-5	5.4	14
307	Towards a better understanding of involuntary detrusor activity. <i>BJU International</i> , <b>2005</b> , 95, 799-803	5.4	14

306	The Midurethral Fascial "Sling on a String": An Alternative to Midurethral Synthetic Tapes in the Era of Mesh Complications. <i>European Urology</i> , <b>2018</b> , 74, 191-196	9.9	14
305	Clinical and Patient-reported Outcome Measures in Men Referred for Consideration of Surgery to Treat Lower Urinary Tract Symptoms: Baseline Results and Diagnostic Findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). <i>European Urology Focus</i> , <b>2019</b> , 5, 340-350	4.9	14
304	Cost-effectiveness of overactive bladder treatments: from the US payer perspective. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 61-71	2	12
303	Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study. <i>World Journal of Urology</i> , <b>2014</b> , 32, 1133-40	3.9	14
302	Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. <i>American Journal of Obstetrics and Gynecology</i> , <b>2012</b> , 206, 444.e1-11	1.9	13
301	INVESTIGATE-I (INvasive Evaluation before Surgical Treatment of Incontinence Gives Added Therapeutic Effect?): study protocol for a mixed methods study to assess the feasibility of a future randomised controlled trial of the clinical utility of invasive urodynamic testing. <i>Trials</i> , <b>2011</b> , 12, 169	2.7	13
300	Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. <i>BMC Urology</i> , <b>2014</b> , 14, 84	2.1	13
299	Functional evidence of nitrergic neurotransmission in the human urinary bladder neck. <i>Neuroscience Letters</i> , <b>2010</b> , 477, 91-4	3.2	13
298	Current and future trends in the management of overactive bladder. <i>International Urogynecology Journal</i> , <b>2007</b> , 18, 81-94	2	13
297	The functional role of beta-adrenoceptor subtypes in mediating relaxation of pig urethral smooth muscle. <i>Journal of Urology</i> , <b>2003</b> , 170, 2508-11	1.5	14
296	Recent advances in pelvic floor repair. <i>F1000Research</i> , <b>2019</b> , 8,	3.5	12
295	Validation of the bladder control self-assessment questionnaire (B-SAQ) in men. <i>BJU International</i> , <b>2014</b> , 113, 783-8	5.4	12
294	Development of two electronic bladder diaries: a patient and healthcare professionals pilot study. <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33, 1101-9	2.3	14
293	Nocturia: current concepts and future perspectives. <i>Acta Physiologica</i> , <b>2013</b> , 207, 53-65	5.4	14
292	How should bladder sensation be measured? ICI-RS 2011. <i>Neurourology and Urodynamics</i> , <b>2012</b> , 31, 370-4.3	4.3	12
291	Urodynamics Useless in Female Stress Urinary Incontinence? Time for Some Sense-A European Expert Consensus. <i>European Urology Focus</i> , <b>2020</b> , 6, 137-145	4.9	12
290	Tissue engineering of the urethra: where are we in 2019?. <i>World Journal of Urology</i> , <b>2020</b> , 38, 2101-2105	3.9	13
289	Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASIfor up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170726	3.6	12

288	Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Phase 2b Dose-Response Study. <i>European Urology Supplements</i> , <b>2005</b> , 4, 25-32	0.1	11
287	Novel muscarinic antagonists to treat incontinence and/or overactive bladder. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2005</b> , 2, 1-6		12
286	Cardiovascular Safety of the $\beta$ -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. <i>Journal of Clinical Pharmacology</i> , <b>2018</b> , 58, 1084-1091	2.8	11
285	Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). <i>International Journal of Urology</i> , <b>2016</b> , 23, 572-9	2.2	13
284	Impact of urinary incontinence on female sexual health in women during midlife. <i>Women's Midlife Health</i> , <b>2015</b> , 1, 6	2.2	10
283	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. <i>European Urology</i> , <b>2019</b> , 75, 129-168	9.9	11
282	Somatic syndromes and chronic pain in women with overactive bladder. <i>Neurourology and Urodynamics</i> , <b>2017</b> , 36, 1113-1118	2.3	10
281	Urinary incontinence in the elderly: part 3 of a series of articles on incontinence. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2010</b> , 107, 531-6	1.9	11
280	The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?. <i>BJU International</i> , <b>2009</b> , 104, 1188-90	5.4	11
279	LUTS/BPH in clinical practice: the importance of nocturia and quality of sleep. <i>BJU International</i> , <b>2006</b> , 98, 3-8	5.4	11
278	The Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management: Introduction and Conclusions. <i>European Urology Supplements</i> , <b>2003</b> , 2, 1-5	0.1	11
277	Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. <i>Neurourology and Urodynamics</i> , <b>2015</b> , 34, 424-8	2.3	10
276	Pelvic floor muscle displacement during voluntary and involuntary activation in continent and incontinent women: a systematic review. <i>International Urogynecology Journal</i> , <b>2015</b> , 26, 1587-98	2	10
275	Overactive bladder - 18 years - Part II. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2016</b> , 42, 199-214	2	10
274	Mechanisms involved in the nitric oxide independent inhibitory neurotransmission to the pig urinary bladder neck. <i>Neurourology and Urodynamics</i> , <b>2011</b> , 30, 151-7	2.3	10
273	A Systematic Review of Surgical interventions for the Treatment of Bladder Pain Syndrome/Interstitial Cystitis. <i>European Urology Focus</i> , <b>2021</b> , 7, 877-885	4.9	10
272	Urological symptom clusters and health-related quality-of-life: results from the Boston Area Community Health Survey. <i>BJU International</i> , <b>2009</b> , 103, 1502-8	5.4	10
271	Morning vs evening dosing with doxazosin in benign prostatic hyperplasia: efficacy and safety. <i>Prostate Cancer and Prostatic Diseases</i> , <b>1998</b> , 1, 163-171	5.9	10

270	Systematic review of therapy for men with overactive bladder. <i>Canadian Urological Association Journal</i> , <b>2011</b> , 5, S143-5	1.2	9
269	What are the origins and relevance of spontaneous bladder contractions? ICI-RS 2017. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, S13-S19	2.3	9
268	Pelvic floor muscle activity during jumps in continent and incontinent women: an exploratory study. <i>Archives of Gynecology and Obstetrics</i> , <b>2018</b> , 297, 1455-1463	2.4	9
267	Is self-reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder?. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 738-42	2.3	9
266	Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. <i>World Journal of Urology</i> , <b>2015</b> , 33, 697-706	3.9	9
265	Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. <i>Neurourology and Urodynamics</i> , <b>2015</b> , 34, 438-43	2.3	9
264	Pelvic floor muscle activity during fast voluntary contractions in continent and incontinent women. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 625-631	2.3	9
263	Use of a simple in vitro fatigue test to assess materials used in the surgical treatment of stress urinary incontinence and pelvic organ prolapse. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 107-115	2.3	9
262	Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck. <i>Journal of Sexual Medicine</i> , <b>2014</b> , 11, 930-941	1	9
261	New once-daily formulation for trossium in overactive bladder. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 1535-1540	2.8	6
260	Incontinence in frail elderly persons: Report of the 6th International Consultation on Incontinence. <i>Neurourology and Urodynamics</i> , <b>2021</b> , 40, 38-54	2.3	8
259	Particulate Versus Non-Particulate Bulking Agents In The Treatment Of Stress Urinary Incontinence. <i>Research and Reports in Urology</i> , <b>2019</b> , 11, 299-310	1.2	8
258	Mitomycin C in the treatment of anterior urethral strictures. <i>Nature Reviews Urology</i> , <b>2018</b> , 15, 717-718	5.3	7
257	Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex. <i>European Urology Focus</i> , <b>2020</b> , 6, 522-530	4.9	8
256	Influence of a distraction task on the involuntary reflex contraction of the pelvic floor muscles following cough. <i>Neurourology and Urodynamics</i> , <b>2017</b> , 36, 160-165	2.3	8
255	535: A Comparison of Muscarinic Receptor-Mediated Function in the Normal and the Neurogenic Overactive Bladder. <i>Journal of Urology</i> , <b>2004</b> , 171, 143-143	1.5	8
254	Adherence to Anticholinergic Therapy and Clean Intermittent Self-Catheterization in Patients With Multiple Sclerosis. <i>International Neurourology Journal</i> , <b>2018</b> , 22, 133-141	2.6	7
253	Association of Pharmacologic Treatment of Urgency Urinary Incontinence With Sleep Quality and Daytime Sleepiness. <i>Obstetrics and Gynecology</i> , <b>2018</b> , 131, 204-211	2	8

252	Bacterial uropathogens and antibiotic susceptibility of positive urine cultures in women with pelvic organ prolapse and urinary incontinence. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 69-73	2.3	6
251	Blockers, 5-Reductase Inhibitors, Acetylcholine, B Agonists, and Phosphodiesterase-5s in Medical Management of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: How Much Do the Different Formulations Actually Matter in the Classes?. <i>Urologic Clinics of North America</i> , <b>2016</b> , 43, 351-6	2.8	7
250	Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2013</b> , 11, 313-8	1.6	7
249	Overactive bladder symptoms and voiding dysfunction in neurologically normal women. <i>Neurourology and Urodynamics</i> , <b>2012</b> , 31, 422-8	2.3	7
248	The assessment of a novel electrical stimulation waveform recently introduced for the treatment of overactive bladder. <i>Physiological Measurement</i> , <b>2013</b> , 34, 479-86	2.7	7
247	Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. <i>European Urology</i> , <b>2021</b> , 79, 492-504	9.9	8
246	The European Association of Urology (EAU) guidelines methodology: a critical evaluation. <i>European Urology</i> , <b>2009</b> , 56, 859-64	9.9	9
245	Urinary urgency - translating the evidence base into daily clinical practice. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1675-82	2.8	8
244	Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder. <i>Obstetrics and Gynecology Clinics of North America</i> , <b>2009</b> , 36, 493-507	3.2	7
243	The Development of the Oral Controlled Absorption System (OCAS <sup>®</sup> ): A New Improved Formulation of Tamsulosin. <i>European Urology Supplements</i> , <b>2005</b> , 4, 1-4	0.1	7
242	Night Time Symptom Control with Omnic (Tamsulosin) Oral Controlled Absorption System (OCAS <sup>®</sup> ). <i>European Urology Supplements</i> , <b>2005</b> , 4, 14-16	0.1	6
241	NK2 tachykinin receptors mediate contraction of the pig intravesical ureter: tachykinin-induced enhancement of non-adrenergic non-cholinergic excitatory neurotransmission. <i>Neurourology and Urodynamics</i> , <b>2001</b> , 20, 297-308	2.3	7
240	Intermittent Catheterization Adherence Scale (ICAS): A new tool for the evaluation of patient adherence with clean intermittent self-catheterization. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 2753-2757	2.3	5
239	Are There Pharmacotherapeutic Options for Underactive Bladder?. <i>European Urology Focus</i> , <b>2018</b> , 4, 6-7	4.9	6
238	Sphincter electromyography in diabetes mellitus and multiple system atrophy. <i>Neurourology and Urodynamics</i> , <b>2015</b> , 34, 669-74	2.3	6
237	What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 288-92	2.3	6
236	Pre- and post-junctional bradykinin B2 receptors regulate smooth muscle tension to the pig intravesical ureter. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 115-21	2.3	6
235	What is the evidence for the management of urethral amyloidosis? A systematic review of the literature. <i>BJU International</i> , <b>2012</b> , 109, 1858-61	5.4	6

234	Which single-item measures of overactive bladder symptom treatment correlate best with patient satisfaction?. <i>Neurourology and Urodynamics</i> , <b>2011</b> , 30, 510-4	2.3	5
233	Overactive Bladder and Continence Guidelines: implementation, inaction or frustration?. <i>International Journal of Clinical Practice</i> , <b>2008</b> , 62, 1588-93	2.8	7
232	Developments in pharmacological therapy for the overactive bladder. <i>BJU International</i> , <b>2006</b> , 98 Suppl 1, 78-87; discussion 88-9	5.4	6
231	Is it possible to make cross-study comparisons of urinary continence rates in patients with overactive bladder?. <i>Current Medical Research and Opinion</i> , <b>2005</b> , 21, 835-7	2.5	6
230	Impact of Dry Mouth on Fluid Intake and Overactive Bladder Symptoms in Women taking Fesoterodine. <i>Journal of Urology</i> , <b>2016</b> , 195, 1517-1522	1.5	5
229	Robotic Surgery as Applied to Functional and Reconstructive Urology. <i>European Urology Focus</i> , <b>2019</b> , 5, 322-328	4.9	4
228	The Impact of Treatment of Overactive Bladder on Physical Activity Limitations. <i>Journal of Women's Health</i> , <b>2016</b> , 25, 801-5	2.9	5
227	Does our limited knowledge of the mechanisms of neural stimulation limit its benefits for patients with overactive bladder? ICI-RS 2013. <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33, 618-21	2.3	4
226	Mechanisms involved in the nitric oxide-induced vasorelaxation in porcine prostatic small arteries. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2011</b> , 384, 245-53	3.3	5
225	Pathophysiology of the lower urinary tract and CNS. <i>Canadian Urological Association Journal</i> , <b>2011</b> , 5, S126-7	1.2	5
224	Anatomy of the lower urinary tract. <i>Surgery</i> , <b>2008</b> , 26, 127-132	0.3	5
223	Botulinum toxin in urinary incontinence. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 255-60	2.7	6
222	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. <i>Blood Pressure Monitoring</i> , <b>2018</b> , 23, 153-163	1.2	5
221	Adrenoceptor signaling regulates proliferation and contraction of human bladder smooth muscle cells under pathological hydrostatic pressure. <i>Journal of Cellular Biochemistry</i> , <b>2019</b> , 120, 17872-17886	4.6	4
220	The development of the ICIQ-UAB: A patient reported outcome measure for underactive bladder. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 996-1004	2.3	5
219	Modern evaluation of lower urinary tract symptoms in 2014. <i>Current Opinion in Urology</i> , <b>2014</b> , 24, 15-20	2.7	5
218	Neuronal and non-neuronal bradykinin receptors are involved in the contraction and/or relaxation to the pig bladder neck smooth muscle. <i>Neurourology and Urodynamics</i> , <b>2014</b> , 33, 558-65	2.3	4
217	Current pharmacotherapy of nocturia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 885-94	3.9	4

216	1367 ONABOTULINUMTOXINA IN PATIENTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE: CONSISTENT EFFECT OVER REPEAT TREATMENT. <i>Journal of Urology</i> , <b>2013</b> , 189,	1.5	4
215	Overactive Bladder in Clinical Practice <b>2012</b> ,		4
214	Anatomy of the lower urinary tract. <i>Surgery</i> , <b>2013</b> , 31, 319-325	0.3	4
213	Chronic urinary retention in men: how we define it, and how does it affect treatment outcome. <i>BJU International</i> , <b>2013</b> , 111, E138-9	5.4	4
212	Mechanisms involved in the adenosine-induced vasorelaxation to the pig prostatic small arteries. <i>Purinergic Signalling</i> , <b>2011</b> , 7, 413-25	3.6	4
211	THE PREVALENCE, BOTHER, AND OVERLAP OF LUTS IN THE US, UK, AND SWEDEN: EPILUTS. <i>European Urology Supplements</i> , <b>2008</b> , 7, 238	0.1	4
210	Another Therapeutic Role for Intravesical Botulinum Toxin: Patients with Long-stay Catheters and Refractory Bladder Pain and Catheter Bypass Leakage. <i>European Urology Focus</i> , <b>2020</b> , 6, 339-343	4.9	4
209	PATHOPHYSIOLOGY OF STRESS INCONTINENCE <b>2008</b> , 301-309		4
208	Recent Advances in treatment of urethral stricture disease in men. <i>F1000Research</i> , <b>2020</b> , 9,	3.5	4
207	3 YEAR PROSPECTIVE FOLLOW-UP OF 91 MEN TREATED WITH TRANSURETHRAL NEEDLE ABLATION OF PROSTATE (TUNA [trade mark sign]). <i>Journal of Urology</i> , <b>1999</b> , 390	1.5	4
206	Pharmacokinetic profile of tamsulosin OCAS. <i>BJU International</i> , <b>2006</b> , 98, 9-12	5.4	4
205	Classification of Mixed Incontinence. <i>European Urology Supplements</i> , <b>2006</b> , 5, 837-841	0.1	4
204	Overview on the lower urinary tract. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 1-14	3.1	4
203	Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT. <i>Health Technology Assessment</i> , <b>2020</b> , 24, 1-122	4.3	4
202	Tissue engineering in urethral reconstruction. <i>F1000 Medicine Reports</i> , <b>2010</b> , 2, 65		4
201	Lower Urinary Tract Symptoms in Elderly Population With Multiple Sclerosis. <i>International Neurourology Journal</i> , <b>2018</b> , 22, 58-64	2.6	3
200	Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 1701-1710	2.3	3
199	Pelvic floor muscle displacement during jumps in continent and incontinent women: An exploratory study. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 2374-2382	2.3	3

198	An estradiol releasing, proangiogenic hydrogel as a candidate material for use in soft tissue interposition. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 1195-1202	2.3	2
197	Review of pelvic and perineal neuromuscular fatigue: Evaluation and impact on therapeutic strategies. <i>Annals of Physical and Rehabilitation Medicine</i> , <b>2018</b> , 61, 345-351	3.6	3
196	Tolterodine in the Treatment of Male LUTS. <i>Current Urology Reports</i> , <b>2015</b> , 16, 60	2.8	3
195	Liquid paraffin is superior to 2% lidocaine gel in reducing urethral pain during urodynamic study in men: A pilot study. <i>Neurourology and Urodynamics</i> , <b>2015</b> , 34, 450-3	2.3	2
194	The use of implanted materials for treating women with pelvic organ prolapse and stress urinary incontinence. <i>Current Opinion in Urology</i> , <b>2019</b> , 29, 431-436	2.7	2
193	Antimuscarinics, $\beta$ Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm. <i>Urologic Clinics of North America</i> , <b>2016</b> , 43, 337-49	2.8	3
192	The Evaluation and Treatment of Adult Nocturnal Enuresis. <i>Current Bladder Dysfunction Reports</i> , <b>2014</b> , 9, 84-89	0.4	3
191	Underlying mechanisms involved in progesterone-induced relaxation to the pig bladder neck. <i>European Journal of Pharmacology</i> , <b>2014</b> , 723, 246-52	5.1	3
190	PI-04 DURABLE REDUCTIONS IN URINARY INCONTINENCE WITH LONG-TERM ONABOTULINUMTOXINA TREATMENT IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME: FINAL RESULTS OF 3.5-YEAR STUDY. <i>Journal of Urology</i> , <b>2015</b> , 193,	1.5	2
189	Endothelin ET(B) receptors are involved in the relaxation to the pig urinary bladder neck. <i>Neurourology and Urodynamics</i> , <b>2012</b> , 31, 688-94	2.3	3
188	Mechanisms involved in endothelin-1-induced contraction of the pig urinary bladder neck. <i>Neurourology and Urodynamics</i> , <b>2012</b> , 31, 156-61	2.3	3
187	Current pharmacotherapy of lower urinary tract symptoms. <i>Surgery</i> , <b>2011</b> , 29, 260-264	0.3	3
186	Open to debate. The Motion: antimuscarinics are the mainstay of therapy for overactive bladder. <i>European Urology</i> , <b>2008</b> , 54, 226-30	9.9	3
185	Female Urethra: Is Ventral the True Dorsal?. <i>European Urology</i> , <b>2020</b> , 78, e218-e219	9.9	3
184	Pharmacologic responses of the mouse urinary bladder. <i>Open Medicine (Poland)</i> , <b>2009</b> , 4, 192-197	2.1	3
183	THE ROLE OF M2 MUSCARINIC RECEPTOR SUBTYPES IN MEDIATING CONTRACTION OF THE PIG BLADDER BASE AFTER CYCLIC ADENOSINE MONOPHOSPHATE ELEVATION AND/OR SELECTIVE M3 INACTIVATION. <i>Journal of Urology</i> , <b>2002</b> , 397-401	1.5	3
182	The contemporary pharmacological management of overactive bladder. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2006</b> , 113, 19-28	3.5	3
181	Introduction and Conclusions. <i>European Urology Supplements</i> , <b>2007</b> , 6, 573-575	0.1	2



180	Effect of short- and long-term sildenafil treatment on erectile dysfunction in rats with partial bladder outlet obstruction. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 108-114	2.3	2
179	Re: Guido Barbagli, Massimo Lazzeri. Clinical Experience with Urethral Reconstruction Using Tissue-engineered Oral Mucosa: A Quiet Revolution. <i>Eur Urol</i> 2015;68:917-918. <i>European Urology</i> , <b>2016</b> , 69, e78-e79	9.9	2
178	Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?. <i>International Urogynecology Journal</i> , <b>2019</b> , 30, 239-244	2	3
177	PD21-01 MULTI-NATIONAL, PROSPECTIVE, RANDOMIZED STUDY OF THE PROSTATIC URETHRAL LIFT (PUL) VS. TRANSURETHRAL RESECTION OF THE PROSTATE (TURP): TWO YEAR RESULTS. <i>Journal of Urology</i> , <b>2016</b> , 195,	1.5	2
176	Epidemiology of Underactive Bladder <b>2017</b> , 25-30		1
175	Synthetic Materials Used in the Surgical Treatment of Pelvic Organ Prolapse: Problems of Currently Used Material and Designing the Ideal Material <b>2018</b> ,		2
174	MP3-01 BPH6 RANDOMIZED STUDY OF PROSTATIC URETHRAL LIFT (PUL) VS TRANSURETHRAL RESECTION OF THE PROSTATE (TURP): OUTCOMES AND PATIENT SATISFACTION. <i>Journal of Urology</i> , <b>2015</b> , 193,	1.5	2
173	Mesh social networking: a patient-driven process. <i>BJU International</i> , <b>2012</b> , 109, E45-6; author reply E46	5.4	1
172	Urethral stricture disease. <i>Surgery</i> , <b>2011</b> , 29, 272-277	0.3	2
171	The management of overactive bladder syndrome: a review of the European Association of Urology Guidelines. <i>Clinical Practice (London, England)</i> , <b>2013</b> , 10, 593-606	0.8	2
170	Anatomy of the lower urinary tract. <i>Surgery</i> , <b>2010</b> , 28, 307-313	0.3	2
169	Management of urinary incontinence in men. <i>Trends in Urology &amp; Men's Health</i> , <b>2020</b> , 11, 18-22	0.3	2
168	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. <i>European Urology Focus</i> , <b>2021</b> , 7, 432-439	4.9	2
167	Tissue engineering: recent advances and review of clinical outcome for urethral strictures. <i>Current Opinion in Urology</i> , <b>2021</b> , 31, 498-503	2.7	1
166	What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine. <i>Neurourology and Urodynamics</i> , <b>2021</b> , 40, 1559-1568	2.3	2
165	THE PREVALENCE OF OAB IN THE US, UK, AND SWEDEN: RESULTS FROM EPILUTS. <i>Journal of Urology</i> , <b>2009</b> , 181, 160-160	1.5	2
164	The Role of M2 Muscarinic Receptor Subtypes Mediating Contraction of the Circular and Longitudinal Smooth Muscle of the Pig Proximal Urethra. <i>Journal of Urology</i> , <b>2002</b> , 308-314	1.5	2
163	Alpha antagonists-from initial concept to routine clinical practice. <i>European Urology</i> , <b>2006</b> , 50, 635-42	9.9	2

162	Lower urinary tract symptoms in men. <i>BMJ, The</i> , <b>2007</b> , 334, 2	5.7	3
161	Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database. <i>Contemporary Clinical Trials Communications</i> , <b>2016</b> , 4, 199-207	1.8	1
160	¿Cuáles el papel de la onabotulinumtoxinA para el tratamiento del complejo de síntomas de vejiga hiperactiva en 2016?. <i>Urologia Colombiana</i> , <b>2016</b> , 25, 69-71	0.1	1
159	MP38-01 LONG-TERM EFFICACY AND SAFETY OF REPEAT ONABOTULINUMTOXINA TREATMENT IN OVERACTIVE BLADDER SYNDROME AND URINARY INCONTINENCE: THIRD INTERIM ANALYSIS, MEDIAN 2.4 YEAR FOLLOW-UP. <i>Journal of Urology</i> , <b>2014</b> , 191,	1.5	1
158	Current pharmacotherapy of lower urinary tract symptoms. <i>Surgery</i> , <b>2014</b> , 32, 292-296	0.3	1
157	Urethral stricture disease. <i>Surgery</i> , <b>2014</b> , 32, 304-309	0.3	1
156	Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder Dysfunction. <i>Current Bladder Dysfunction Reports</i> , <b>2012</b> , 7, 51-58	0.4	1
155	Focus on nocturia in the elderly. <i>Aging Health</i> , <b>2013</b> , 9, 389-402		1
154	Systematic review of therapy for men with overactive bladder. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 5, 143	1.2	1
153	Overview of Evidence for Contemporary Management of Lower Urinary Tract Symptoms Presumed Due to Benign Prostatic Hyperplasia in Males. <i>European Urology Supplements</i> , <b>2010</b> , 9, 482-485	0.1	1
152	1518 ONABOTULINUMTOXINA IN PATIENTS WITH URINARY INCONTINENCE DUE TO NEUROGENIC DETRUSOR OVERACTIVITY: EFFECTS ON HEALTH-RELATED QUALITY OF LIFE. <i>Journal of Urology</i> , <b>2011</b> , 185,	1.5	1
151	Investigation and management of urinary incontinence in men. <i>Trends in Urology &amp; Men's Health</i> , <b>2010</b> , 1, 27-30	0.3	1
150	Nocturia: not just the elderly. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 666-7	2.8	1
149	Editorial comment on: the use of lingual mucosal graft in adult anterior urethroplasty: surgical steps and short-term outcome. <i>European Urology</i> , <b>2008</b> , 54, 676	9.9	1
148	PNFLBA-09 LONG-TERM COMBINATION TREATMENT WITH SOLIFENACIN AND MIRABEGRON IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH OVERACTIVE BLADDER. <i>Journal of Urology</i> , <b>2017</b> , 197,	1.5	1
147	The logistical management of tertiary urethral disease in the United Kingdom: Implications from an online audit of male reconstructive urethral surgery. <i>Journal of Clinical Urology</i> , <b>2020</b> , 13, 288-294	0.2	1
146	Treatment decision-making among men with lower urinary tract symptoms: A qualitative study of men's experiences with recommendations for patient-centred practice. <i>Neurourology and Urodynamics</i> , <b>2021</b> , 40, 201-210	2.3	3
145	Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5	1

144	Reply to David R. Staskin and Michael G. Oefelein's Letter to the Editor re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. <i>Eur Urol</i> 2008;54:543-52. <i>European Urology</i> , 2009, 55, e51	9.9	1
143	Words of wisdom. Re: Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. <i>European Urology</i> , 2009, 55, 748	9.9	1
142	Words of wisdom. Re: Lingual mucosal graft urethroplasty for anterior urethral reconstruction. <i>European Urology</i> , 2009, 55, 752-3	9.9	
141	BOTULINUM TOXIN ATTENUATES SENSORY AFFERENT NERVE FIRING IN AN EX VIVO MOUSE BLADDER MODEL. <i>Journal of Urology</i> , 2009, 181, 82-83	1.5	1
140	Acute urinary retention: who is at risk and how best to manage it?. <i>Current Urology Reports</i> , 2006, 7, 252-258		1
139	Introduction and Conclusions. <i>European Urology Supplements</i> , 2007, 6, 695-700	0.1	1
138	The Oral Controlled Absorption System (OCAS <sup>®</sup> ): The Evolution of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH). <i>European Urology Supplements</i> , 2005, 4, 20-22	0.1	1
137	Urology. Introduction. <i>Urology</i> , 2003, 62, 1-5	1.5	1
136	Clinical study of benign prostatic disease, current concepts and future prospects: randomized controlled trials versus real life practice. <i>Current Opinion in Urology</i> , 2003, 13, 1-5	2.7	1
135	Towards patient-driven criteria in overactive bladder management. <i>International Journal of Clinical Practice</i> , 2004, 58, 2-3	2.8	1
134	331 Tissue-engineered buccal mucosa - in vitro contraction and stress testing. <i>European Urology Supplements</i> , 2004, 3, 85	0.1	1
133	Randomized controlled trials for benign prostatic obstruction: problems and pitfalls. <i>BJU International</i> , 2000, 85 Suppl 1, 54-7	5.4	1
132	Laparoscopic colposuspension - a new procedure. <i>Minimally Invasive Therapy and Allied Technologies</i> , 1993, 2, 59-62		1
131	Urinary tract fistulae. <i>Current Opinion in Urology</i> , 1993, 3, 234-240	2.7	1
130	The contemporary clinical treatment of female stress incontinence. <i>International Urogynecology Journal</i> , 1994, 5, 112-118	2	1
129	Fistulae and gynaecological injury to the urinary tract. <i>Current Opinion in Urology</i> , 1995, 5, 191-194	2.7	1
128	Failure of Urinary Drainage: Lower Tract 2007, 118-131		
127	Role of Surgery in Bladder Pain Syndrome. <i>Current Bladder Dysfunction Reports</i> , 2021, 16, 87-96	0.4	1

126	Prostate Surgery for Men with Lower Urinary Tract Symptoms: Do We Need Urodynamics to Find the Right Candidates? Exploratory Findings from the UPSTREAM Trial.. <i>European Urology Focus</i> , <b>2021</b> ,	4.9	2
125	Skin Substitutes: Burn Treatment and beyond 258-277		1
124	Physiology and Pharmacology of the Prostate <b>2020</b> , 127-150		
123	Harninkontinenz <b>2019</b> , 211-252		1
122	Non-Hormonal treatment of BPH/BOO. <i>Indian Journal of Urology</i> , <b>2014</b> , 30, 194-201	0.8	1
121	Tissue engineering as a potential alternative or adjunct to surgical reconstruction in treating pelvic organ prolapse: comment on Boennelycke et al. <i>International Urogynecology Journal</i> , <b>2013</b> , 24, 881	2	1
120	Urinary incontinence in adults. <i>Surgery</i> , <b>2011</b> , 29, 254-259	0.3	0
119	Inkontinenz im Alter. <i>CME (Berlin, Germany)</i> , <b>2014</b> , 11, 7-16	0	0
118	Results of the patient report of intermittent catheterization experience (PRICE) study. <i>Neurourology and Urodynamics</i> , <b>2021</b> , 40, 2008-2019	2.3	0
117	Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes. <i>European Urology Focus</i> , <b>2021</b> , 7, 1176-1183	4.9	0
116	Involuntary reflexive pelvic floor muscle training in addition to standard training versus standard training alone for women with stress urinary incontinence: a randomized controlled trial. <i>International Urogynecology Journal</i> , <b>2021</b> , 1	2	0
115	Determinants and impact of the time to perform clean intermittent self-catheterization on patient adherence and quality of life: A prospective observational study. <i>Neurourology and Urodynamics</i> , <b>2021</b> , 40, 1027-1034	2.3	
114	Future Directions in Evaluating Nocturia and Its Impact in Patients with LUTS/BPH. <i>European Urology Supplements</i> , <b>2006</b> , 5, 19-21	0.1	0
113	What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4	
112	Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms. <i>Trials</i> , <b>2021</b> , 22, 745	2.7	
111	Overview of the Evaluation of Lower Urinary Tract Dysfunction <b>2011</b> , 261-282		0
110	Botulinum Toxin Versus Neural Stimulation. <i>European Urology Focus</i> , <b>2017</b> , 3, 530-532	4.9	
109	The overactive bladder: where are we in 2016?. <i>Trends in Urology &amp; Men's Health</i> , <b>2016</b> , 7, 13-16	0.3	

108 Urethral Disorders **2016**, 303-320

107 Reply to Bernhard Liedl, Klaus Goeschen, and Florian Wagenlehner's Letter to the Editor re: Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. *Eur Urol* **2019**, *75*:988-1000. *European Urology*, **2019**, *76*, e107-e108 9.9

106 Multi-criteria decision analysis modelling to help physicians optimise treatment in patients diagnosed with overactive bladder. *European Urology Supplements*, **2019**, *18*, e1995-e1996 0.1

105 Benefit-risk evaluation of approved pharmacotherapies for the treatment of overactive bladder: A sensitivity analysis of benefits versus safety for individual OAB symptoms using multi-criteria decision analysis modelling. *European Urology Supplements*, **2019**, *18*, e1993-e1994 0.1

104 Medical Aspects of the Treatment of LUTS/BPH: Antimuscarinic and  $\beta$ -Agonists **2018**, 207-215

103 Diagnosis and treatment of overactive bladder **2018**, 489-495

102 Lidocaine gel should be more effective in reducing urethral pain during urodynamic study in men: Re: Stav K, Taleb E, Sabler IM, Siegel YI, Beberashvili I, Zisman A. Liquid paraffin is superior to 2% lidocaine gel in reducing urethral pain during urodynamic study in men: A pilot study. *Neurourol Urodyn*. **2014**;34:450-3. *Neurourology and Urodynamics*, **2015**, *34*, 454-5 2.3

101 Moving beyond BPH - A contemporary update on male LUTS. *Asian Journal of Urology*, **2019**, *6*, 208-209 2.5

100 872 Cardiovascular (CV) assessments in a randomized, double-blind, phase 3b trial of mirabegron add-on treatment in incontinent overactive bladder (OAB) patients with an inadequate response to solifenacin monotherapy. *European Urology Supplements*, **2016**, *15*, e872 0.1

99 What is the role of onabotulinumtoxinA for the management of the overactive bladder symptom complex in 2016?. *Urologia Colombiana*, **2016**, *25*, 72-74 0.1

98 The autologous fascia mid-urethral sling on a string is a viable and effective alternative to synthetic tape surgery. *European Urology Supplements*, **2017**, *16*, e1509-e1510 0.1

97 Tissue Engineering and Cell Therapy for Underactive Bladder: Current and Future Approaches **2017**, 75-82

96 Indications for Treatment **2017**, 31-37

95 Another therapeutic role for intravesical botulinum toxin A: Patients with severe bladder spasm with long stay catheters. *European Urology Supplements*, **2018**, *17*, e1359 0.1

94 Contemporary issues with pharmacotherapy for lower urinary tract symptoms. *International Journal of Clinical Practice*, **2014**, *68*, 541-2 2.8

93 Antimuscarinics **2014**, 100-112

92 110 Development of tissue engineered bio-absorbable cellularised mesh for stress urinary incontinence and pelvic organ prolapse: The effect of chemical and mechanical stimulation on improving tensile properties. *European Urology Supplements*, **2013**, *12*, e110 0.1

91 Words of wisdom: Re: The challenges facing academic urology training programs: an impending crisis. *European Urology*, **2013**, *64*, 511-2 9.9

- 90 Reply from Authors re: Margit M. Fisch. Validated Patient-reported Outcome Measure: A Step Forward to Improve Patient Counselling Before Urethral Reconstruction. *Eur Urol* 2013;64:783-7. *European Urology*, **2013**, 64, 784-785 9.9
- 89 744 OnabotulinumtoxinA 100U demonstrates similar treatment effect in overactive bladder patients with urinary incontinence regardless of number of prior anticholinergics taken or reason for their inadequate management of patients' overactive bladder. *European Urology Supplements*, **2013**, 11, e111 0.1
- 88 Reply from author re: Stephan Madersbacher. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. *Eur Urol* 2013;64:257-9: OnabotulinumtoxinA for idiopathic overactive bladder symptoms: some answers but even more questions. *European Urology*, **2013**, 64, e100-1 9.9
- 87 Epidemiology of overactive bladder **2013**, 6-15
- 86 OnabotulinumtoxinA for the treatment of overactive bladder. *Clinical Investigation*, **2014**, 4, 281-286
- 85 150. Long-term efficacy and safety of onabotulinumtoxinA treatment in overactive bladder syndrome and urinary incontinence: interim analysis with median 2.4 years follow-up. *Toxicon*, **2015**, 93, S46-S47 1.6
- 84 The role of co-medication in the treatment of OAB **2015**, 118-128
- 83 Bladder outlet obstruction and the overactive bladder **2015**, 222-232
- 82 Botulinum toxin therapy for the management of lower urinary tract symptoms [has this come of age?]. *Drug Discovery Today: Therapeutic Strategies*, **2012**, 9, e35-e39
- 81 What was hot at the ICS meeting Glasgow, Scotland, 2011. *Neurourology and Urodynamics*, **2012**, 31, 2-6 2.3
- 80 Contemporary Combination Therapy in the Treatment of LUTS/BPH. *Current Bladder Dysfunction Reports*, **2013**, 8, 134-141 0.4
- 79 Hyperammonemic Encephalopathy Approximately 40 Years after Urinary Diversion for Bladder Exstrophy: A Case Report. *Current Urology*, **2011**, 5, 109-112 1.7
- 78 Pathophysiology of urinary incontinence. *Surgery*, **2011**, 29, 249-253 0.3
- 77 Reply to Stephen Shei-Dei Yang and Shang-Jen Chang's Letter to the Editor re: Christopher R. Chapple, Francesco Montorsi, Teuvo L.J. Tammela, et al. Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe. *Eur Urol* 2011;60:103-10. *Current Bladder Dysfunction Reports*, **2011**, 6, 70-73 9.9
- 76 What Is the Evidence for the Use of Botulinum Toxin in Idiopathic Detrusor Overactivity?. *Current Bladder Dysfunction Reports*, **2011**, 6, 70-73 0.4
- 75 Pathophysiology of the lower urinary tract and CNS. *Canadian Urological Association Journal*, **2013**, 5, 126 1.2
- 74 Para-Urethral Leiomyoma: A Case Report and Discussion of Diagnosis and Management. *British Journal of Medical and Surgical Urology*, **2010**, 3, 30-32
- 73 Cystomanometry **2011**, 49-96

72	Troubles de la vidange et obstruction sous-vésicale <b>2011</b> , 121-141	
71	Urological diagnosis [history and investigations. <i>Surgery</i> , <b>2010</b> , 28, 323-330	0.3
70	Nocturia and the danger of falls. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 527-8	2.8
69	Urological diagnosis [history and investigations. <i>Surgery</i> , <b>2008</b> , 26, 154-160	0.3
68	Pathophysiology of urinary incontinence. <i>Surgery</i> , <b>2008</b> , 26, 188-192	0.3
67	THE EFFECT OF A SUBSTANCE RELEASED FROM THE MUCOSA THAT MAY ACTIVATE SPONTANEOUS CONTRACTILITY IS PRONOUNCED IN A RAT MODEL OF BLADDER OUTLET OBSTRUCTION AND INVOLVE MUSCARINIC RECEPTORS. <i>Journal of Urology</i> , <b>2008</b> , 179, 126-126	1.5
66	ADD-ON TOLTERODINE EXTENDED RELEASE IMPROVES OVERACTIVE BLADDER SYMPTOMS IN MEN RECEIVING $\beta$ BLOCKER THERAPY. <i>Journal of Urology</i> , <b>2008</b> , 179, 443-443	1.5
65	THE IMPACT OF LOWER URINARY TRACT SYMPTOMS ON MEN'S SEXUAL HEALTH: RESULTS FROM EpiLUTS. <i>Journal of Urology</i> , <b>2008</b> , 179, 361-362	1.5
64	THE IMPACT OF LOWER URINARY TRACT SYMPTOMS ON WOMEN'S SEXUAL HEALTH: RESULTS FROM THE EpiLUTS STUDY. <i>Journal of Urology</i> , <b>2008</b> , 179, 536-536	1.5
63	Excision of a symptomatic unusual duplicated urethra in an adult male. <i>Journal of Clinical Urology</i> , <b>2017</b> , 10, 77-79	0.2
62	Which procedure for stress urinary incontinence? Autologous fascial slings. <i>Current Opinion in Urology</i> , <b>2020</b> , 30, 277-278	2.7
61	Contemporary Outcomes of Surgery for Primary and Recurrent Genitourinary Fistulae in a Well-resourced Country. <i>European Urology Open Science</i> , <b>2021</b> , 31, 41-46	0.1
60	Comparison of Supine and Prone Positioning in Female Patients Undergoing Urethral Diverticulum Excision. <i>Journal of Urological Surgery</i> , <b>2021</b> , 8, 50-53	0.1
59	Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , <b>2021</b> , 27, 759-765	1.9
58	Reply to Helmut Madersbacher and Klaus-Peter Jöemann Letter to the Editor re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. <i>Eur Urol</i> 2008;54:543B2. <i>European Urology</i> , <b>2009</b> , 56, e50-e52	9.9
57	Lower urinary tract symptoms: new perspectives on prevalence, burden and comorbidities. Introduction. <i>BJU International</i> , <b>2009</b> , 103 Suppl 3, 1-3	5.4
56	SUCCESS OF ACUPUNCTURE IN THE TREATMENT OF PAINFUL BLADDER SYNDROME (INTERSTITIAL CYSTITIS). <i>Journal of Urology</i> , <b>2009</b> , 181, 23-23	1.5
55	THE IMPACT OF OAB ON MALE SEXUAL HEALTH: RESULTS FROM EpiLUTS. <i>Journal of Urology</i> , <b>2009</b> , 181, 369-369	1.5

- 54 THE ROLE OF THE MUCOSA IN MEDIATING RESPONSES TO  $\beta$ ADRENOCEPTOR AGONISTS IN PIG BLADDER TRIGONE AND PROXIMAL URETHRA. *Journal of Urology*, **2009**, 181, 150-150 1.5
- 53 Acute urinary retention: Who is at risk and how best to manage it?. *Current Prostate Reports*, **2006**, 4, 25-32
- 52 1188: Efficacy of Fesoterodine in Patients with Overactive Bladder (OAB): Improvements in OAB Symptoms and Health-Related Quality of Life (HRQL). *Journal of Urology*, **2007**, 177, 392-392 1.5
- 51 What's hot from the ICS Annual Meeting 2006. *Neurourology and Urodynamics*, **2007**, 26, 148-153 2.3
- 50 Re: Edgar AD, Levin R, Constantinou CE, et al. 2007. A critical review of the pharmacology of the plant extract of *Pygeum africanum* in the treatment of LUTS. *Neurourol Urodynam* 26:458-463. *Neurourology and Urodynamics*, **2007**, 26, 464-464 2.3
- 49 A pragmatic approach to the primary care management of men with lower urinary tract symptoms. *International Journal of Clinical Practice*, **2007**, 61, 1423-5 2.8
- 48 Response to P. Hilton: of porcupines and poodles-a joint challenge to industry and the profession. *International Urogynecology Journal*, **2007**, 18, 835; author reply 837 2
- 47 Questions and Answers Addressed During the Tamsulosin OCAS Meeting. *European Urology Supplements*, **2005**, 4, 23-24 0.1
- 46 Assessing the patient with a urological problem. *Foundation Years*, **2005**, 1, 1-7
- 45 Vesicovaginal and Rectovaginal Fistula Repair **2006**, 235-249
- 44 Desensitisation of purinergic receptors enhances neurogenic detrusor responses in the bladder dome of the pig. *European Urology Supplements*, **2003**, 2, 73 0.1
- 43 The Diagnosis of Urinary Incontinence: Urodynamics, More or Less?. *European Urology Supplements*, **2002**, 1, 25-28 0.1
- 42 Female urology. *Current Opinion in Urology*, **2005**, 15, 211-212 2.7
- 41 MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER. *BJU International*, **2000**, 85, 33-46 5.4
- 40 Konsensus-Bericht: Beckenbodenschwäche der älteren Frau. *Der Urologe Ausg B*, **1998**, 38, S19-S22
- 39 Screening and Diagnostic Considerations in Benign Prostatic Hyperplasia. *Disease Management and Health Outcomes*, **1997**, 2, 178-188
- 38 The investigation of female stress incontinence. *International Urogynecology Journal*, **1994**, 5, 119-124 2
- 37 Management of Hyperparathyroidism in Pregnancy. *Obstetrical and Gynecological Survey*, **1990**, 45, 377 0.5



- 36 PD33-09 CAN METABOLIC SYNDROME AFFECT THE EFFICACY OUTCOMES OF COMBINATION THERAPY WITH DAILY TADALAFIL 5MG PLUS TAMSULOSIN 0.4MG IN MEN WITH LUTS AND ED?. *Journal of Urology*, **2020**, 203, e708 1.5
- 35 Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? *Eur Urol* 2020;78:e218-9. *European Urology*, **2021**, 81, e16-e16 9.9
- 34 Medical, Behavioural and Minimally Invasive Therapy [A Urologist's View **2005**, 181-197
- 33 Functional independence measure predicts the outcome of clean intermittent catheterization training in patients with multiple sclerosis. *Annals of Physical and Rehabilitation Medicine*, **2021**, 65, 1015<sup>36</sup> 3.9
- 32 Male Urinary Incontinence: Assessment and Management **2021**, 1159-1167
- 31 Current Trends in Urethral Stricture Management **2020**, 443-456
- 30 Clinical Evaluation of the Lower Urinary Tract **2020**, 63-74
- 29 69: Development and Characterisation of Tissue-Engineered Buccal Mucosa for Urethroplasty. *Journal of Urology*, **2004**, 171, 18-18 1.5
- 28 Poster 33: Solifenacin Significantly Reduced Incontinence Episodes and Increased the Percentage of Continent Patients Compared to Tolterodine ER in an Overactive Bladder Study (STAR). *Journal of Pelvic Medicine & Surgery*, **2005**, 11, S40
- 27 1206: Enhanced Urothelial ATP Release in Bladders of Patients with Neurogenic Detrusor Overactivity. *Journal of Urology*, **2005**, 173, 327-327 1.5
- 26 1441: Second Messenger Pathways Involved in  $\alpha$  - Adrenoceptor Mediated Contraction of the Human Prostate. *Journal of Urology*, **2005**, 173, 390-391 1.5
- 25 1265: ATP Released from the Urothelium of Bladder with Idiopathic Detrusor Overactivity. *Journal of Urology*, **2006**, 175, 407-407 1.5
- 24 . *Japanese Journal of Urology*, **2007**, 98, 337
- 23 423: Inhibitory Effects of B-Adrenoceptor Agonists on Pig Bladder Dome Involve the B-Adrenoceptor Subtype and the Urothelium. *Journal of Urology*, **2007**, 177, 141-141 1.5
- 22 Urological Injuries **2018**, 243-248
- 21 Combination Pharmacotherapy for Overactive Bladder **2019**, 133-148
- 20 APP-085-PM ?????B????????????????????(?????????,97????????????). *Japanese Journal of Urology*, **2009**, 100, 167
- 19 Antimuscarinic Treatments in Overactive Bladder 170-177

- 18 Troubles du remplissage et incontinence **2011**, 97-119
- 17 Troubles de la sensibilité **2011**, 143-149
- 16 Urodynamique de l'enfant **2011**, 167-171
- 15 Évaluation clinique du bas appareil urinaire **2011**, 1-6
- 14 Méthodes urodynamiques **2011**, 19-47
- 13 Current Concepts of Anterior Urethral Pathology: Management and Future Directions **2011**, 415-435
- 12 ES3 Overactive bladder : pathophysiology and management A contemporary update. *Japanese Journal of Urology*, **2011**, 102, 74
- 11 JS-6 Anterior urethral surgery : current concepts and future directions(The 6th JUA, UAA, EAU and AUA Joint Session). *Japanese Journal of Urology*, **2011**, 102, 100
- 10 Fondements morphologiques, fonctionnels et du contrôle du bas appareil urinaire **2011**, 7-17
- 9 Vessie rétractée **2011**, 151-154
- 8 Vessies neurogènes **2011**, 155-166
- 7 Special Populations **2012**, 125-141
- 6 Pharmacological Treatment of Overactive Bladder **2012**, 83-113
- 5 Contemporary management of overactive bladder **2013**, 2-5
- 4 Urolume Stents in the Management of Benign Prostatic Hyperplasia **2012**, 117-140
- 3 Spezielle Urodynamik des Mannes **2022**, 387-410
- 2 Is Pharmacotherapy for Benign Prostatic Hyperplasia an Alternative? **1992**, 155-171
- 1 Are Metallic Endourological Stents an Alternative to Prostatectomy in the Management of Benign Prostatic Hyperplasia? **1992**, 95-108

